Natural history and clinical effect of aortic valve regurgitation after left ventricular assist device implantation

ObjectivesAortic valve regurgitation reduces left ventricular assist device mechanical efficiency. Evidence has also suggested that left ventricular assist device implantation can induce or exacerbate aortic valve regurgitation. However, this has not been compared with aortic valve regurgitation progression in a nonsurgical end-stage heart failure population. Furthermore, its clinical effect is unclear. We sought to characterize the development and progression of aortic valve regurgitation in left ventricular assist device recipients and to identify its clinical effect.MethodsA review of all consecutive patients who received an intracorporeal left ventricular assist device at Duke University Medical Center from January 2004 to January 2011 was conducted. Cases of previous or concomitant aortic valve surgery were excluded. Data from the remaining implants (n = 184) and a control group of contemporaneous nonsurgical patients with end-stage heart failure (n = 132) were analyzed. Serial transthoracic echocardiography was used to characterize aortic valve regurgitation as a function of time.ResultsLeft ventricular assist device implantation was associated with worsening aortic valve regurgitation, defined as an increase in aortic valve regurgitation grade, relative to the nonsurgical patients with end-stage heart failure (P < .0001). The recipients of continuous flow left ventricular assist devices were more likely than recipients of pulsatile left ventricular assist devices to develop worsening aortic valve regurgitation (P = .0348). Moderate or severe aortic valve regurgitation developed in 21 left ventricular assist device recipients; this was unrelated to the type of device implanted (continuous vs pulsatile; P = .754) or aortic valve regurgitation grade before left ventricular assist device implantation (P = .42). Five patients developed severe aortic valve regurgitation; all of whom underwent aortic valve procedures.ConclusionsNative aortic valve regurgitation developed and/or progressed after left ventricular assist device implantation, with this effect being more pronounced in continuous flow left ventricular assist device recipients. However, the preoperative aortic valve regurgitation grade failed to correlate with the development of substantial aortic valve regurgitation after left ventricular assist device implantation. After left ventricular assist device implantation, aortic valve regurgitation had a small, but discernible, clinical effect, with some patients developing severe aortic valve regurgitation and requiring aortic valve procedures. These data have implications for the long-term management of left ventricular assist device recipients, in particular as the durability of implantable continuous flow left ventricular assist device therapy improves

The Role of Implantable Cardioverter Defibrillators for the Prevention of Ventricular Arrhythmia in Left Ventricular Assist Device Recipients

Advanced heart failure represents a significant strain on our health care system and is associated with increased morbidity and mortality. New device therapies, including left ventricular assist device (LVAD) implantation, have transformed management as both a destination therapy and as a bridge to transplantation. Although LVADs have improved patient outcomes, arrhythmias represent a significant and costly complication of this therapy. In recent years, implantable cardioverter-defibrillators (ICDs) have been developed to reduce the incidence of lethal arrhythmia. However, a gap in the literature exists for both guidelines in prevention of early ventricular arrhythmia (VA) in LVAD recipients and the effectiveness of ICDs when paired with various LVADs. Here, we clarify these guidelines and show that ICD selection should be tailored to the type of LVAD. We also show that subcutaneous ICDs represent an attractive alternative option for certain cohorts of patients, although transvenous ICDs remain a first-line choice at this time. Ultimately, understanding the various management options that affect outcomes in heart failure patients is important for treatment and clinical decision-making in an ever-growing population

Predicting normal glenoid version from the pathologic scapula: a comparison of 4 methods in 2- and 3-dimensional models

Correction of pathologic glenoid retroversion improves gleonhumeral mechanics and reduces glenoid component wear after total shoulder arthroplasty. Determining the amount of correction necessary can be difficult because of the wide range of normal glenoid version. We hypothesize that normal glenoid version can be predicted in a pathologic shoulder based on conserved relationships between the anterior glenoid wall, Resch angle, and the internal structures of the glenoid vault. Three-dimensional (3-D) computer tomography (CT) scan-based measurements of the anterior glenoid wall angle (AGWA), Resch angle (RA), and glenoid version were made in 58 scapulae from the Haeman-Todd Osteological Collection (Museum of Natural History in Cleveland, OH) and 19 paired scapulae from patients with unilateral osteoarthritis. Linear regression equations derived from the AGWA and RA and from a computer-generated vault model were used to predict native (nonpathologic) glenoid version as defined by the 19 nonpathologic scapula. Linear regression equations based on the measured AGWA or RA, as well as the glenoid vault model in the 19 pathologic scapulae, were able to accurately predict native glenoid version in the contralateral nonpathologic shoulder. This study demonstrates the ability to take 3-D CT scan-based measurements in a scapula with pathologic glenoid retroversion and predict the native (nonpathologic) glenoid version in the contralateral shoulder by using linear regression equations or a computer generated vault model. Such tools might assist in preoperative planning and intraoperative decision making to allow correction of pathologic glenoid retroversion